| Title | Author(s) | Year | View Count |
 | Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay | Seto, WK; Tanaka, Y; Wong, DKH; Lai, CL; Shinkai, N; Yuen, JCH; Tong, T; Fung, J; Hung, IFN; Yuen, MF | 2013 | 73 |
| Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir | Seto, WK; Liu, K; Fung, J; Wong, DKH; Yuen, JCH; Hung, IFN; Lai, CL; Yuen, MF | 2012 | 76 |
 | A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B | Seto, WK; Lai, CL; Ip, PPC; Fung, J; Wong, DKH; Yuen, JCH; Hung, IFN; Yuen, MF | 2012 | 108 |
| A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance | Seto, WK; Wong, DKH; Fung, J; Hung, IFN; Fong, DYT; Yuen, JCH; Tong, T; Lai, CL; Yuen, MF | 2012 | 83 |
| High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B | Seto, WK; Wong, DKH; Fung, J; Ip, PPC; Yuen, JCH; Hung, IFN; Lai, CL; Yuen, MF | 2012 | 100 |
 | Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B | Seto, WKW; Wong, DKH; Fung, JYY; Hung, IFN; Yuen, JCH; Tong, T; Lai, CL; Yuen, RMF | 2012 | 10 |
| Serologic and virologic kinetics after stopping nucleoside analogue therapy in hepatitis B surface antigen (HBSAG) seroclearance | Seto, WK; Wong, DKH; Fung, J; Yuen, JCH; Hung, IFN; Lai, CL; Yuen, RMF | 2012 | 50 |
| High prediction of hepatitis B surface antigen (HBsAg) seroclearance at 3 years of follow-up by measuring HBsAg titers | Seto, WK; Lai, CL; Fung, J; Wong, D; Yuen, JCH; Young, JLP; Tong, TSM; Hung, IFN; Yuen, MF | 2011 | 47 |
| Evidence of serologic activity in chronic hepatitis B after surface antigen (HBSAG) seroclearance | Seto, WK; Tanaka, Y; Wong, D; Lai, CL; Shinkai, N; Yuen, JCH; Tong, TSM; Fung, J; Hung, IFN; Yuen, MF | 2011 | 49 |
| Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome | Seto, WK; Lai, CL; Fung, J; Wong, DKH; Yuen, JCH; Hung, IFN; Yuen, MF | 2011 | 210 |
| Three years of continuous entecavir therapy in treatment-nave chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety | Yuen, MF; Seto, WK; Fung, J; Wong, DKH; Yuen, JCH; Lai, CL | 2011 | 1,308 |
| Elevation of ALT fails to predict significant histologic abnormalities in chronic hepatitis B patients. | Seto, WK; Lai, CL; Fung, JYY; Yuen, JCH; Wong, DKH; Yuen, RMF | 2011 | 123 |
| Serum hepatitis B surface antigen (HBSAG) titers and HBV DNA levels in Hepatitis B E antigen (HBEAG)-negative chronic Hepatitis B: an interim analysis | Seto, WK; Lai, CL; Fung, J; Wong, D; Yuen, JCH; Young, JLP; Tong, TSM; Hung, IFN; Yuen, MF | 2011 | 44 |
| HBV DNA levels after 12 weeks of telbivudine treatment in chronic hepatitis B predicts long-term outcome | Seto, WK; Lai, CL; Fung, J; Wong, D; Yuen, JCH; Hung, IFN; Yuen, MF | 2010 | 177 |
| Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: A study of a large blood donor population | Yuen, MF; Lee, CK; Wong, DKH; Fung, J; Hung, I; Hsu, A; But, DYK; Cheung, TK; Chan, P; Yuen, JCH; Fung, FKC; Seto, WK; Lin, CK; Lai, CL | 2010 | 631 |
| Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B | Yuen, MF; Tanaka, Y; Fong, DYT; Fung, J; Wong, DKH; Yuen, JCH; But, DYK; Chan, AOO; Wong, BCY; Mizokami, M; Lai, CL | 2009 | 438 |
| Increase risk of HBeAg-negative chronic hepatitis B with older age at HBeAg seroconversion | Fung, JYY; Lai, CL; Wong, DKH; Yuen, JCH; Yuen, RMF | 2009 | 144 |
| Association of hepatitis B virus pre-S deletions with the risk of development of hepatocellular carcinoma | Yeung, P; Wong, DKH; Fung, JYY; Yuen, JCH; Fung, FKC; Lai, CL; Yuen, RMF | 2009 | 182 |
| Increase risk of HBeAg-negative chronic hepatitis B with older age at HBeAg seroconversion | Fung, JYY; Lai, CL; Wong, DKH; Yuen, JCH; Yuen, RMF | 2009 | 146 |
| Combination of baseline HBV DNA and ALT levels with on-treatment HBV DNA response to select HBeAg-positive patients for lamivudine therapy | Fung, JYY; Lai, CL; Seto, WK; Wong, DKH; Yuen, JCH; Yuen, RMF | 2009 | 260 |
|
